To examine whether MDM2i mediated p53 activation impairs LSC engraftment potential, we used a transplantable model of CML-like disease (SCL-tTA-BCR-ABL-inducible transgene) (Supplementary Fig. 5a)31. This evidence concerns the gene TP53 and chronic myelogenous leukemia, BCR-ABL1 positive.